Strong report.
Highlights for me (not limited to this)
AIPAC subgroup data looking good. TACTI-002 on right track
Covid (Efti), autoimmune(imp761) and Immuno-Incology "diagnostics" front through collaboration with LabCorp.
Data will do the talking and hopefully the flow of data will be as anticipated and as is progressing, and hopefully with good results, again indications are so far positive.
Of course one of the 3 pipelines with GSK with imp731 has hit a snag but (a) these things are expected in clinical research, (b) that is not our focus product, (c) does not affect other products as mechanism is different and (d) as was the case with AIPAC, we better wait and see what GSK will learn, once assessing the data.
Looking forward to 2021.
Strong report.Highlights for me (not limited to this)AIPAC...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
0.005(1.12%) |
Mkt cap ! $534.9M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 45.5¢ | 44.0¢ | $432.5K | 968.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 10175 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 26893 | 2 |
View Market Depth
| Last trade - 16.10pm 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
44.5¢ |
Change
0.005 ( 0.16 %) |
||||
| Open | High | Low | Volume | ||
| 44.5¢ | 45.5¢ | 44.5¢ | 305959 | ||
| Last updated 15.59pm 27/05/2024 ? | |||||
| IMM (ASX) Chart |